Substrate
financeSourced

NexPoint Diversified Real Estate Trust Accepts Resignation of Director Brian Mitts

The board of NexPoint Diversified Real Estate Trust received the resignation of director Brian Mitts effective June 1 2026. The departure triggers mandatory Form 8-K disclosures and requires the board to determine whether to fill the vacancy or operate with a reduced number of directors.

SEC EDGAR — NEXPOINT DIVERSIFIED REAL ESTATE TRUST
1 source·Jun 1, 8:00 PM·1m read
NexPoint Diversified Real Estate Trust Accepts Resignation of Director Brian Mittsprnewswire.com
Audio version
Tap play to generate a narrated version.

DALLAS, June 2, 2026 — NexPoint Diversified Real Estate Trust reported that director Brian Mitts resigned from the board effective June 1 2026, according to an 8-K filed with the SEC on June 2.

The filing discloses the resignation under Item 5.02 with no cause cited. Mitts had served as a director of the trust, which is externally managed by an affiliate of NexPoint Advisors and holds a diversified portfolio of real estate assets.

The trust also reported results from its annual meeting of security holders under Item 5.07. Specific vote tallies were included in the exhibits furnished under Item 9.01.

WHAT IT CHANGES: Prior to June 1 the board operated with its full complement of directors. As of that date the board has one fewer member. The filing does not indicate whether the board has appointed a replacement or intends to reduce its size. Under SEC rules the company must disclose any subsequent election of a new director on a Form 8-K within four business days.

WHY IT MATTERS DOWNSTREAM: The resignation requires the remaining directors to evaluate board composition and committee assignments in advance of the trust’s next quarterly filing and any upcoming debt or equity offerings that may require updated governance disclosures.

If the board size is permanently reduced, shareholder voting thresholds for certain actions under the trust’s declaration of trust and Maryland law will adjust accordingly. The company must also update its director and officer questionnaires and D&O insurance disclosures to reflect the change.

This marks the latest board-level change at NexPoint Diversified Real Estate Trust following a series of filings in 2025 that addressed executive compensation and advisory agreements. The trust’s shares trade on the NYSE under the ticker NXDT. The SEC filing constitutes the primary public record of the resignation and meeting results.

Coverage spread

Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.

No mainstream coverage of this story has surfaced yet.

Transparency

Confidence90%

Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.

Related Stories

U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effectthehindu.com
finance43 min ago

U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect

A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.

FI
FI
OS
BBC News
4 sources
Fed Chairman Names Two Outside Advisers During Transitionprnewswire.com
finance43 min ago

Fed Chairman Names Two Outside Advisers During Transition

Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.

FI
Wall Street Journal
2 sources
Forte Biosciences Accepts Resignation of Director David Veitchinsidermonkey.com
finance2 hrs agoSourced

Forte Biosciences Accepts Resignation of Director David Veitch

Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…

SEC EDGAR — Forte Biosciences, Inc. (FBRX)
1 source